Related Experiment Videos
Direct thrombin inhibitor use during percutaneous coronary intervention
Spyros Kokolis1, Luther T Clark, Erdal Cavusoglu
1State University of New York Health Science Center at Brooklyn, Brooklyn, New York 11203, USA.
Journal of Cardiovascular Pharmacology
|February 24, 2005
Summary
Direct thrombin inhibitors (DTIs) offer new anticoagulant options for patients undergoing percutaneous coronary intervention (PCI). This review examines their properties and clinical evidence in PCI patients.
Area of Science:
- Pharmacology
- Cardiology
- Thrombosis
Background:
- Unfractionated heparin and indirect thrombin inhibitors are standard anticoagulants for percutaneous coronary intervention (PCI).
- Emerging direct thrombin inhibitors (DTIs) present alternative antithrombotic strategies.
- Optimizing anticoagulation in PCI is crucial for preventing thrombotic complications.
Purpose of the Study:
- To review the pharmacological characteristics of direct thrombin inhibitors (DTIs).
- To evaluate the clinical data supporting the use of DTIs in patients undergoing PCI.
- To compare DTIs with existing anticoagulant therapies in the context of PCI.
Main Methods:
- Literature review of pharmacological studies on DTIs.
- Systematic evaluation of clinical trials and observational studies involving DTIs in PCI.
- Analysis of efficacy and safety data from relevant publications.
Main Results:
- DTIs exhibit distinct pharmacokinetic and pharmacodynamic profiles compared to traditional anticoagulants.
- Clinical data demonstrate the efficacy of DTIs in reducing thrombotic events during and after PCI.
- Safety profiles, including bleeding risks, are being established for DTIs in the PCI population.
Conclusions:
- Direct thrombin inhibitors represent a promising class of anticoagulants for PCI.
- Further research and real-world data are essential to fully define the role of DTIs in interventional cardiology.
- DTIs may offer tailored antithrombotic solutions for specific patient subgroups undergoing PCI.